Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arthrokehlan is a homeopathic and isopathic remedy developed by Sanum-Kehlbeck, derived from the microorganism *Propionibacterium acnes* (also known as *Cutibacterium acnes*). As a core component of the Sanum therapy system, it is primarily indicated for the treatment of chronic inflammatory conditions, particularly those affecting the joints (such as arthritis, arthrosis, and ankylosing spondylitis) and the skin (such as acne vulgaris). The preparation follows the principles of isopathy, utilizing specific dilutions of the microorganism to stimulate the body's immune response and address microbial imbalances associated with chronic disease. It is commercially available in several dosage forms, including oral drops, ointments for topical application, and injectable ampoules for subcutaneous or intramuscular administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on arthrokehlan.